Author:
Mohammed Ousman,Alemayehu Ermiyas,Bisetegn Habtye,Tilahun Mihret,Gedefie Alemu,Ebrahim Endris,Fiseha Mesfin,Necho Mogesie,Fiseha Temesgen
Abstract
Abstract
Background
Globally, the human immunodeficiency virus has been recognized as a major public health concern. The direct toxicity of antiretroviral medicines or their active metabolites causes liver cell destruction by different mechanisms, inducing immune-mediated inflammation, oxidative stress, and other mechanisms. On the other hand, the virus itself also produces hepatotoxicity. Therefore, this systematic review and meta-analysis aimed to assess the pooled prevalence of hepatotoxicity among HIV-infected patients in Ethiopia.
Methods
PubMed, Science Direct, Cochrane Library, Web of Science, and ResearchGate databases were used to find relevant articles. As well, various professional associations were searched to retrieve grey literature. The Newcastle–Ottawa Quality Assessment Scale was used to assess the quality of recruited studies. The data were extracted using Microsoft Excel, and the meta-analysis was carried out using STATA 14 software. I2 and Cochran’s Q test were employed to assess the presence of heterogeneity between studies. A random effect model was used. The funnel plot and Egger’s statistics were used to assess publication bias. Moreover, subgroup analysis and sensitivity analysis were also done.
Results
The pooled prevalence of hepatotoxicity among HIV patients in Ethiopia was 25.45% (95% CI = 20.06–30.84%). There was high heterogeneity, with an I2 value of 93.7%. Subgroup analysis by HAART status showed a higher pooled prevalence of hepatotoxicity among HIV patients taking HAART (23.63%) than among HAART naive patients (7.29%). In subgroup analysis, the pooled prevalence of hepatotoxicity among HIV/Tb co-infected and HIV mono-infected patients was 26.3% and 17.94%, respectively.
Conclusion
The current systematic review and meta-analysis showed a high prevalence of hepatotoxicity among HIV-infected patients. Therefore, regular monitoring of hepatotoxicity among HIV-infected patients is required in order to avoid liver damage and other complications.
Systematic review registration PROSPERO (2022:CRD42022334704)
Publisher
Springer Science and Business Media LLC
Reference80 articles.
1. Okolie MN, Eghafona NO, Omoregie R. Anti-human immunodeficiency virus agents. J Med Lab Sci. 2003;12(1):1–14.
2. De Cock KM, Mbori-Ngacha D, Marum E. Shadow on the continent: public health and HIV/AIDS in Africa in the 21st century. The Lancet. 2002;360(9326):67–72.
3. Adebisi YA, Rabe A, Ekpenyong A, Okereke M, Sarah OA. Towards 90–90-90 target: COVID-19 and HIV response in Africa. J Infect Dis Epidemiol. 2021;7:191.
4. Dean HD, Fenton KA. Integrating a social determinants of health approach into public health practice: a five-year perspective of actions implemented by CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Public Health Rep. 2013;128(6_suppl3):5–11.
5. Pepperrell T, Hill A, Moorhouse M, Clayden P, McCann K, Sokhela S, et al. Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. J Virus Erad. 2020;6(2):70–3.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献